Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by NAOTO T UENO and LEI HUO.
NAOTO T UENO
Connection Strength
2.786
LEI HUO
  1. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.246
  2. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):236.
    View in: PubMed
    Score: 0.244
  3. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
    View in: PubMed
    Score: 0.241
  4. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.227
  5. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.225
  6. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.206
  7. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.
    View in: PubMed
    Score: 0.157
  8. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017; 12(9):e0185231.
    View in: PubMed
    Score: 0.151
  9. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. Breast Cancer Res Treat. 2016 11; 160(1):101-109.
    View in: PubMed
    Score: 0.141
  10. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46.
    View in: PubMed
    Score: 0.136
  11. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer. 2014 Jun 15; 120(12):1775-9.
    View in: PubMed
    Score: 0.118
  12. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus. 2013; 2:409.
    View in: PubMed
    Score: 0.114
  13. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124.
    View in: PubMed
    Score: 0.059
  14. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.056
  15. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.053
  16. NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. J Natl Cancer Inst. 2022 04 11; 114(4):579-591.
    View in: PubMed
    Score: 0.052
  17. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
    View in: PubMed
    Score: 0.050
  18. NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers (Basel). 2020 Dec 10; 12(12).
    View in: PubMed
    Score: 0.047
  19. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
    View in: PubMed
    Score: 0.042
  20. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol. 2018 Feb 17; 149(3):253-261.
    View in: PubMed
    Score: 0.039
  21. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8).
    View in: PubMed
    Score: 0.034
  22. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in?Breast Cancer. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):791-9.
    View in: PubMed
    Score: 0.034
  23. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res. 2014 Jul 23; 33:58.
    View in: PubMed
    Score: 0.030
  24. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
    View in: PubMed
    Score: 0.029
  25. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer. 2014 Jun; 14(3):e81-8.
    View in: PubMed
    Score: 0.029
  26. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Dec 15; 117(24):5476-84.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.